|
MRI News Service:
Contrast Agents p16 |
|
|
|
 |
 | | | 'The overall objective of this study was to develop a nanoparticle formulation for dual modality imaging of head and neck cancer. Here, we report the synthesis and characterization of polymeric phospholipid-based nanomicelles encapsulating near-infrared ...' | | Saturday, 27 November 2010 by 7thspace.com |
|
|
|
| | | 'Gadonanotubes (GNTs) developed at Rice University are beginning to show positive results in a study funded by a federal stimulus grant through the National Institutes of Health (NIH) last year. The study has determined GNTs are effective in helping ...' | | | Tuesday, 16 November 2010 by www.sciencedaily.com | |
|
|
|
| | | 'Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the Canadian launch of ABLAVAR® (gadofosveset trisodium injection), a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent. ...' | | | Thursday, 14 October 2010 by www.radiopharm.com | |
|
|
|
| | | 'Taiwan researchers have developed the world's first multimodal molecular imaging contrast agent using iron-platinum alloy (FePt) nanoparticles that can be used in clinical settings. The research was published as a cover story in the Sept. 29 edition ...' | | | Wednesday, 29 September 2010 by www.taiwantoday.tw | |
|
|
|
| | | 'Covidien (NYSE:COV), a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, ...' | | | Friday, 10 September 2010 by investor.covidien.com | |
|
|
|
| | | ' Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, supports the U.S. Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare ...' | | | Friday, 10 September 2010 by www.radiopharm.com | |
|
|
|
| | | 'The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF), if the drug is ...' | | | Thursday, 9 September 2010 by www.fda.gov | |
|
|
|
| | | 'Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field. ...' | | | Friday, 13 August 2010 by www.sciencedaily.com | |
|
|
|
| | | 'Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have ...' | | | Monday, 2 August 2010 by www.healthnewsdigest.com | |
|
|
|
| | | 'Spotting a single cancerous cell that has broken free from a tumor and is traveling through the bloodstream to colonize a new organ might seem like finding a needle in a haystack. But a new imaging technique from the University of Washington is a first ...' | | | Monday, 26 July 2010 by www.sciencedaily.com | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
The major difference between a thing that might go wrong and a thing that
cannot possibly go wrong is that when a thing that cannot possibly go wrong
goes wrong it usually turns out to be impossible to get at or repair.
-
Douglas Adams |
|
|
News
top
